The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years
Open accessAbstract
Purpose: Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group is unknown. Methods: A total of 5,489 patients ≥ 75 years of age with resected stage III CC, diagnosed between 2004 and 2007, were selected from four data sets containing demographic, stage, treatment, and survival information. These data sets included SEER-Medicare, a linkage between the New York State Cancer Registry (NYSCR) and its Medicare programs, and prospective cohort studies Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) and the National Comprehensive Cancer Network. Data sets were analyzed in parallel using covariate adjusted and propensity score (PS) matched proportional hazards models to evaluate the effect of treatment on survival. PS trimming was used to mitigate the effects of selection bias. Results: Use of adjuvant therapy declined with age and comorbidity. Chemotherapy receipt was associated with a survival benefit of comparable magnitude to clinical trials results (SEER-Medicare PS-matched mortality, hazard ratio [HR], 0.60; 95% CI, 0.53 to 0.68). The incremental benefit of oxaliplatin over non–oxaliplatin-containing regimens was also of similar magnitude to clinical trial results (SEER-Medicare, HR, 0.84; 95% CI, 0.69 to 1.04; NYSCR-Medicare, HR, 0.82, 95% CI, 0.51 to 1.33) in two of three examined data sources. However, statistical significance was inconsistent. The beneficial effect of chemotherapy and oxaliplatin did not seem solely attributable to confounding. Conclusion: The noninvestigational experience suggests patients with stage III CC ≥ 75 years of age may anticipate a survival benefit from adjuvant chemotherapy. Oxaliplatin offers no more than a small incremental benefit. Use of adjuvant chemotherapy after the age of 75 years merits consideration in discussions that weigh individual risks and preferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Self-citationImmortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry
Piccirillo, J. F. (2004) · JAMA · doi:10.1001/jama.291.20.2441 · Cited by 1,205
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Cited by
Papamichael, D., Audisio, R. A., Glimelius, B., de Gramont, A., Glynne-Jones, R., Haller, D., Köhne, C.-H., Rostoft, S., Lemmens, V., Mitry, E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu253 · Cited by 471
Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0213 · Cited by 343
Stürmer, T., Wyss, R., Glynn, R. J., & Brookhart, M. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12197 · Cited by 302
Self-citationLin, C. C., Bruinooge, S. S., Kirkwood, M. K., Olsen, C., Jemal, A., Bajorin, D., Giordano, S. H., Goldstein, M., Guadagnolo, B. A., Kosty, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1558 · Cited by 263
Making sense of adjuvant chemotherapy in colorectal cancer
Chan, G. H. J., & Chee, C. E. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.06.03 · Cited by 82
Metadata
- Authors
- Sanoff, H. K., Carpenter, W. R., Stürmer, T., Goldberg, R. M., Martin, C. F., Fine, J. P., McCleary, N. J., Meyerhardt, J. A., Niland, J., Kahn, K. L., Schymura, M. J., & Schrag, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-20
- Volume
- 30
- Issue
- 21
- Pages
- 2624-2634
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138446143
- Cited by
- 271
- References
- 29
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. https://app.cochat.ai/papers/10.1200/jco.2011.41.1140
- The paper
- Sanoff, H. K., Carpenter, W. R., Stürmer, T., Goldberg, R. M., Martin, C. F., Fine, J. P., McCleary, N. J., Meyerhardt, J. A., Niland, J., Kahn, K. L., Schymura, M. J., & Schrag, D. (2012). Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.41.1140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.